• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

儿童癌症幸存者的心脏毒性:回顾性队列研究

Cardiotoxicity in Pediatric Cancer Survivorship: Retrospective Cohort Study.

作者信息

Mansoor Masab, Ibrahim Andrew

机构信息

Edward Via College of Osteopathic Medicine, 4408 Bon Aire Drive, Monroe, LA, 71203, United States, 1 504-521-3500.

Texas Tech University Health Sciences Center School of Medicine, Lubbock, TX, United States.

出版信息

JMIRx Med. 2025 Jul 31;6:e65299. doi: 10.2196/65299.

DOI:10.2196/65299
PMID:40743465
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12312988/
Abstract

BACKGROUND

Improved survival rates in pediatric cancer have shifted focus to long-term effects of treatment, with cardiovascular complications emerging as a leading cause of morbidity and mortality. Understanding the patterns and predictors of cardiotoxicity is crucial for risk stratification, treatment optimization, and long-term care planning.

OBJECTIVE

This study investigated the prevalence, incidence, and risk factors of cardiotoxicity in pediatric cancer survivors using data from the Childhood Cancer Survivor Study.

METHODS

We conducted a retrospective cohort study of 24,938 five-year survivors of childhood cancer diagnosed between 1970 and 1999. Cardiovascular complications, including cardiomyopathy, coronary artery disease, valvular heart disease, and arrhythmias, were assessed through self-reported questionnaires and medical record review. Cox proportional hazards models were used to evaluate risk factors, and a prediction model was developed using multivariable logistic regression.

RESULTS

The cumulative incidence of any cardiovascular complication by 30 years postdiagnosis was 18.7% (95% CI 17.9%-19.5%). Significant risk factors included anthracycline exposure (hazard ratio 2.31, 95% CI 2.09-2.55 for doses ≥250 mg/m²), chest radiation (hazard ratio 1.84, 95% CI 1.66-2.05 for doses ≥20 Gy), older age at diagnosis, male sex, and obesity. A risk prediction model demonstrated good discrimination (C statistic 0.78, 95% CI 0.76-0.80). Survivors had a significantly higher risk of cardiovascular complications compared with sibling controls (odds ratio 3.7, 95% CI 3.2-4.2).

CONCLUSIONS

Childhood cancer survivors face a substantial and persistent risk of cardiovascular complications. The identified risk factors and prediction model can guide personalized follow-up strategies and interventions. These findings underscore the need for lifelong cardiovascular monitoring and care in this population.

摘要

背景

儿童癌症存活率的提高使人们将重点转向治疗的长期影响,心血管并发症已成为发病和死亡的主要原因。了解心脏毒性的模式和预测因素对于风险分层、治疗优化和长期护理规划至关重要。

目的

本研究利用儿童癌症幸存者研究的数据,调查了儿童癌症幸存者心脏毒性的患病率、发病率和危险因素。

方法

我们对1970年至1999年间诊断出的24938名儿童癌症五年幸存者进行了一项回顾性队列研究。通过自我报告问卷和病历审查评估心血管并发症,包括心肌病、冠状动脉疾病、瓣膜性心脏病和心律失常。使用Cox比例风险模型评估危险因素,并使用多变量逻辑回归开发预测模型。

结果

诊断后30年时,任何心血管并发症的累积发病率为18.7%(95%置信区间17.9%-19.5%)。显著的危险因素包括蒽环类药物暴露(剂量≥250mg/m²时,风险比为2.31,95%置信区间2.09-2.55)、胸部放疗(剂量≥20Gy时,风险比为1.84,95%置信区间1.66-2.05)、诊断时年龄较大、男性性别和肥胖。风险预测模型显示出良好的区分度(C统计量为0.78,95%置信区间0.76-0.80)。与同胞对照相比,幸存者发生心血管并发症的风险显著更高(优势比为3.7,9%置信区间3.2-

相似文献

1
Cardiotoxicity in Pediatric Cancer Survivorship: Retrospective Cohort Study.儿童癌症幸存者的心脏毒性:回顾性队列研究
JMIRx Med. 2025 Jul 31;6:e65299. doi: 10.2196/65299.
2
Nutritional interventions for survivors of childhood cancer.儿童癌症幸存者的营养干预措施。
Cochrane Database Syst Rev. 2016 Aug 22;2016(8):CD009678. doi: 10.1002/14651858.CD009678.pub2.
3
Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.两种现代生存预测工具 SORG-MLA 和 METSSS 在接受手术联合放疗和单纯放疗治疗有症状长骨转移患者中的比较。
Clin Orthop Relat Res. 2024 Dec 1;482(12):2193-2208. doi: 10.1097/CORR.0000000000003185. Epub 2024 Jul 23.
4
Platinum-induced hearing loss after treatment for childhood cancer.儿童癌症治疗后铂诱导的听力损失。
Cochrane Database Syst Rev. 2016 Aug 3;2016(8):CD010181. doi: 10.1002/14651858.CD010181.pub2.
5
Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer.儿童癌症治疗期间及治疗后用于治疗蒽环类药物引起的有症状和无症状心脏毒性的医学干预措施。
Cochrane Database Syst Rev. 2016 Aug 23;2016(8):CD008011. doi: 10.1002/14651858.CD008011.pub3.
6
Early and late renal adverse effects after potentially nephrotoxic treatment for childhood cancer.儿童癌症潜在肾毒性治疗后的早期和晚期肾脏不良反应。
Cochrane Database Syst Rev. 2013 Oct 8(10):CD008944. doi: 10.1002/14651858.CD008944.pub2.
7
AI-based Hepatic Steatosis Detection and Integrated Hepatic Assessment from Cardiac CT Attenuation Scans Enhances All-cause Mortality Risk Stratification: A Multi-center Study.基于人工智能的心脏CT衰减扫描检测肝脂肪变性及综合肝脏评估可增强全因死亡风险分层:一项多中心研究
medRxiv. 2025 Jun 11:2025.06.09.25329157. doi: 10.1101/2025.06.09.25329157.
8
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.在基层医疗机构或医院门诊环境中,如果患者出现以下症状和体征,可判断其是否患有 COVID-19。
Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3.
9
Interventions for weight reduction in obesity to improve survival in women with endometrial cancer.肥胖症减肥干预措施以提高子宫内膜癌女性的生存率。
Cochrane Database Syst Rev. 2023 Mar 27;3(3):CD012513. doi: 10.1002/14651858.CD012513.pub3.
10
Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer.儿童癌症治疗期间及治疗后用于治疗蒽环类药物引起的有症状和无症状心脏毒性的医学干预措施。
Cochrane Database Syst Rev. 2011 Sep 7(9):CD008011. doi: 10.1002/14651858.CD008011.pub2.

本文引用的文献

1
Targeting estrogen receptor signaling for treating heart failure.针对雌激素受体信号通路治疗心力衰竭。
Heart Fail Rev. 2024 Jan;29(1):125-131. doi: 10.1007/s10741-023-10356-9. Epub 2023 Oct 3.
2
Cancer statistics, 2023.癌症统计数据,2023 年。
CA Cancer J Clin. 2023 Jan;73(1):17-48. doi: 10.3322/caac.21763.
3
Primary cardioprotection with dexrazoxane in patients with childhood cancer who are expected to receive anthracyclines: recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group.
预期接受蒽环类药物治疗的儿童癌症患者的初级心脏保护:国际儿童癌症晚期效应指南协调组的建议。
Lancet Child Adolesc Health. 2022 Dec;6(12):885-894. doi: 10.1016/S2352-4642(22)00239-5. Epub 2022 Sep 27.
4
Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group.儿童癌症幸存者心肌病监测建议:国际儿童癌症长期效应指南协调小组报告
Lancet Oncol. 2015 Mar;16(3):e123-36. doi: 10.1016/S1470-2045(14)70409-7.
5
Aging and risk of severe, disabling, life-threatening, and fatal events in the childhood cancer survivor study.《儿童癌症幸存者研究中衰老与严重、致残、危及生命和致死事件风险》
J Clin Oncol. 2014 Apr 20;32(12):1218-27. doi: 10.1200/JCO.2013.51.1055. Epub 2014 Mar 17.
6
Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association.接受癌症治疗的儿童、青少年和年轻成年人的长期心血管毒性:病理生理学、病程、监测、管理、预防及研究方向:美国心脏协会的科学声明
Circulation. 2013 Oct 22;128(17):1927-95. doi: 10.1161/CIR.0b013e3182a88099. Epub 2013 Sep 30.
7
Modifiable risk factors and major cardiac events among adult survivors of childhood cancer.儿童癌症成年幸存者的可改变风险因素和主要心脏事件。
J Clin Oncol. 2013 Oct 10;31(29):3673-80. doi: 10.1200/JCO.2013.49.3205. Epub 2013 Sep 3.
8
Clinical ascertainment of health outcomes among adults treated for childhood cancer.成年癌症患儿治疗后的健康结局的临床确认。
JAMA. 2013 Jun 12;309(22):2371-2381. doi: 10.1001/jama.2013.6296.
9
Cardiovascular risk factors in hematopoietic cell transplantation survivors: role in development of subsequent cardiovascular disease.造血干细胞移植幸存者的心血管危险因素:在随后发生心血管疾病中的作用。
Blood. 2012 Nov 29;120(23):4505-12. doi: 10.1182/blood-2012-06-437178. Epub 2012 Oct 3.
10
Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment.蒽环类药物心脏毒性:患病率、发病机制与治疗
Curr Cardiol Rev. 2011 Nov;7(4):214-20. doi: 10.2174/157340311799960645.